EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia



Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia



Journal of Clinical Oncology 18(3): 547-561



Purpose: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). Patients and Methods: Adults with newly diagnosed ALL referred since 1992 were entered onto the study; treatment was initiated in 204 patients between 1992 and January 1998. No exclusions were made because of older age, poor performance status, organ dysfunction, or active infection. Median age was 39.5 years; 37% were at least 50 years old. Mature B-cell disease (Burkitt type) was present in 9%, T-cell disease in 17%. Leukocytosis of more than 30 X 109/L was found in 26%, Philadelphia chromosome-positive disease in 16% (20% of patients with assessable metaphases), CNS leukemia at the time of diagnosis in 7%, and a mediastinal mass in 7%. Treatment consisted of four cycles of Hyper-CVAD alternating with four cycles of high-dose methotrexate (MTX) and cytarabine therapy, together with intrathecal CNS prophylaxis and supportive care with antibiotic prophylaxis and granulocyte colony-stimulating factor therapy. Maintenance in patients with nonmature B-cell ALL included 2 years of treatment with mercaptopurine, MTX, vincristine, and prednisone (POMP). Results: Overall, 185 patients (91%) achieved complete remission (CR) and 12 (6%) died during induction therapy. Estimated 5-year survival and 5-year CR rates were 39% and 38%, respectively. The incidence of CNS relapse was low (4%). Compared with 222 patients treated with vincristine, doxorubicin, and dexamethasone (VAD) regimens, our patients had a better CR rate (91% v 75%, P < .01) and CR rate after one course (74% v 55%, P < .01) and better survival (P < .01), and a smaller percentage had more than 5% day 14 blasts (34% v 48%, P = .01). Previous prognostic models remained predictive for outcome with Hyper-CVAD therapy. Conclusion: Hyper-CVAD therapy is superior to our previous regimens and should be compared with established regimens in adult ALL.

(PDF emailed within 0-6 h: $19.90)

Accession: 011295973

Download citation: RISBibTeXText

PMID: 10653870

DOI: 10.1200/jco.2000.18.3.547



Related references

Update of the hyper-CVAD dose-intensive regimen in adult acute lymphocytic leukemia. Blood 92(10 SUPPL 1 PART 1-2): 313A, Nov 15, 1998

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101(12): 2788-2801, 2004

The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematology/Oncology Clinics of North America 14(6): 1381-96, X-Xi, 2001

Modified Burkitt regimen for adult acute lymphocytic leukemia The hyper-CVAD program. Blood 82(10 SUPPL 1): 329A, 1993

Modified Burkitt therapy in adult acute lymphocytic leukemia The hyper-CVAD regimen. Annals of Hematology 68(2): A10, 1994

Update of the modified hyper-CVAD regimen in newly diagnosed adult acute lymphocytic leukemia. Blood 102(11): 880a, November 16, 2003

Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia. Leukemia Research 32(6): 930-935, 2007

Treatment of adult acute lymphocytic leukemia with Hyper-CVAD Experience in a county teaching hospital. Blood 96(11 Part 2): 213b, November 16, 2000

Treatment of Adult Acute Lymphoblastic Leukemia with the Hyper-CVAD Regimen Preliminary Analysis from a Single Center. Blood 100(11): Abstract No 4617, November 16, 2002

Clinical characteristics and treatment outcome of adult acute lymphoblastic leukemia with t(4;11)(q21;q23) using a modified hyper-CVAD regimen. Acta Haematologica 122(1): 23-26, 2009

Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 94(2): 285-291, 2002

Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers. ChemoTherapy 60(4): 219-223, 2015

Update of the hyper-CVAD and imatinib mesylate regimen in Philadelphia positive acute lymphocytic leukemia. Blood 102(11): 225a-226a, November 16, 2003

Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia. Zhonghua Yi Xue Za Zhi 91(20): 1384-1387, 2012

Update of the modified hyper-CVAD regimen with or without rituximab as frontline therapy of adults with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (ILL). 2007